Binding, uptake and degradation of human recombinant interleukin-2 (125 ala) in activated human T- and B-lymphocytes and in monocyte-macrophages

2008 ◽  
Vol 29 (5) ◽  
pp. 257-272 ◽  
Author(s):  
C. M. Petersen ◽  
B. S. Christiansen ◽  
K. Kaltoft
2021 ◽  
pp. 11-18
Author(s):  
O.A. Gizinger

The article shows the scheme of complex therapy of bacterial meningitis using the recombinant cytokine interleukin 2. The clinical, immunological and microbiological efficacy of the use of recombinant interleukin 2 in the complex therapy of bacterial meningitis is shown. The biological effects of recombinant IL-2 justify its use in the complex therapy of meningitis due to its influence on the activity of metabolic processes at the cellular and subcellular levels, the ability to stabilize the system of lipid peroxidation of cell membranes, to influence the processes of clonal proliferation and differentiation of T- and B-lymphocytes improving the quality of the therapy.


2022 ◽  
pp. 28-33
Author(s):  
Oksana Anatolievna Gizinger ◽  
◽  
Irina Yurievna Lepina ◽  
Marina Nikolaevna Bagdasaryan ◽  
◽  
...  

The article analyzes the pathogenetic features of bacterial meningitis and substantiates the scheme of complex therapy of the disease using the recombinant cytokine interleukin-2 (IL2). The clinical, immunological and microbiological efficacy of the complex therapy scheme has been revealed. It has been shown that the pleiotropic effects of recombinant IL-2, its effect on the activity of metabolic processes at the cellular and subcellular levels, the ability to stabilize the system of lipid peroxidation of cell membranes, the ability to influence the processes of clonal proliferation and differentiation of T- and B-lymphocytes, make its use justified in complex therapy of meningitis.


1991 ◽  
Vol 174 (3) ◽  
pp. 561-569 ◽  
Author(s):  
P S Linsley ◽  
W Brady ◽  
M Urnes ◽  
L S Grosmaire ◽  
N K Damle ◽  
...  

Functional interactions between T and B lymphocytes are necessary for optimal activation of an immune response. Recently, the T lymphocyte receptor CD28 was shown to bind the B7 counter-receptor on activated B lymphocytes, and subsequently to costimulate interleukin 2 production and T cell proliferation. CTLA-4 is a predicted membrane receptor from cytotoxic T cells that is homologous to CD28 and whose gene maps to the same chromosomal band as the gene for CD28. It is not known, however, if CD28 and CTLA-4 also share functional properties. To investigate functional properties of CTLA-4, we have produced a soluble genetic fusion between the extracellular domain of CTLA-4 and an immunoglobulin C gamma chain. Here, we show that the fusion protein encoded by this construct, CTLA4Ig, bound specifically to B7-transfected Chinese hamster ovary cells and to lymphoblastoid cells. CTLA4Ig also immunoprecipitated B7 from cell surface 125I-labeled extracts of these cells. The avidity of 125I-labeled B7Ig fusion protein for immobilized CTLA4Ig was estimated (Kd approximately 12 nM). Finally, we show that CTLA4Ig was a potent inhibitor of in vitro immune responses dependent upon cellular interactions between T and B lymphocytes. These findings provide direct evidence that, like its structural homologue CD28, CTLA-4 is able to bind the B7 counter-receptor on activated B cells. Lymphocyte interactions involving the B7 counter-receptor are functionally important for alloantigen responses in vitro.


2019 ◽  
Author(s):  
Margarita A Dudina ◽  
Andrey A Savchenko ◽  
Sergey A Dogadin ◽  
Alexandr G Borisov ◽  
Igor V Kudryavcev ◽  
...  

1986 ◽  
Vol 83 (10) ◽  
pp. 3427-3431 ◽  
Author(s):  
J. Hackett ◽  
G. C. Bosma ◽  
M. J. Bosma ◽  
M. Bennett ◽  
V. Kumar

Blood ◽  
1989 ◽  
Vol 74 (4) ◽  
pp. 1355-1359 ◽  
Author(s):  
MX Zhou ◽  
HW Jr Findley ◽  
AH Ragab

Abstract We are reporting here that low-mol wt B-cell growth factor (LMW-BCGF) and recombinant interleukin-2 (rIL-2) are together able to induce CD3+ cytotoxic T lymphocytes (CTL) with lymphokine-activated killer cell (LAK) activity from the bone marrow (BM) cells of children with acute lymphoblastic leukemia (ALL). Ficoll-Hypaque (FH)-separated BM cells were obtained from patients with active disease (at diagnosis N = 13, in relapse N = 15) and in complete remission (CR; N = 12). CD3+ cells were removed by Leu-4 antibody and immunobeads. Cells were cultured (10(5) cells/mL) in semisolid media with rIL-2 (100 mu/mL), LMW-BCGF (0.1 mu/mL), and the combination of rIL-2 plus LMW-BCGF, respectively, for seven to ten days. Pooled colonies were harvested for phenotyping. LMW-BCGF plus rIL-2 induced large numbers of CD3+ colonies from CD3- precursors. rIL-2 alone did not induce colony formation. In addition, cells were cultured in liquid media with LMW-BCGF, rIL-2, and the combination of LMW-BCGF plus rIL-2, respectively, for seven to 21 days. They were harvested for phenotyping, and cytotoxicity assays were performed v K562, Raji, and autologous leukemic cells. LMW-BCGF plus rIL-2 induced significant expansion of CD3+ cells from CD3- precursors, and these cells were activated to kill autologous leukemic cells in addition to Raji and K562 cell lines. LMW-BCGF or rIL-2 alone did not induce significant expansion or activation of cytotoxic CD3- cells. Our hypothesis is that LMW-BCGF plus rIL-2 stimulates the proliferation and activation of CD3- precursors from the BM cells of children with acute leukemia to become CD3+ cells that have LAK activity. This finding may have therapeutic implications.


1985 ◽  
Vol 9 (1) ◽  
pp. 87-102 ◽  
Author(s):  
Harris A. Lewin ◽  
William C. Davis ◽  
Domenico Bernoco

Sign in / Sign up

Export Citation Format

Share Document